S.A. Mason LLC Sells 1,453 Shares of Pfizer Inc. (NYSE:PFE)

S.A. Mason LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 16.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,386 shares of the biopharmaceutical company’s stock after selling 1,453 shares during the quarter. S.A. Mason LLC’s holdings in Pfizer were worth $213,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. Front Street Capital Management Inc. lifted its holdings in Pfizer by 4.3% during the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock worth $268,000 after purchasing an additional 215 shares in the last quarter. Graves Light Lenhart Wealth Inc. lifted its holdings in shares of Pfizer by 1.4% in the second quarter. Graves Light Lenhart Wealth Inc. now owns 19,863 shares of the biopharmaceutical company’s stock worth $729,000 after buying an additional 281 shares in the last quarter. Infrastructure Capital Advisors LLC boosted its position in shares of Pfizer by 5.2% in the second quarter. Infrastructure Capital Advisors LLC now owns 5,751 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 284 shares during the period. Castleview Partners LLC boosted its position in shares of Pfizer by 2.4% in the first quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 287 shares during the period. Finally, United Bank grew its stake in Pfizer by 0.6% during the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after acquiring an additional 290 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $27.77 on Thursday. The company has a 50-day simple moving average of $27.47 and a two-hundred day simple moving average of $29.47. Pfizer Inc. has a 12-month low of $25.61 and a 12-month high of $42.22. The firm has a market cap of $157.25 billion, a price-to-earnings ratio of 77.14, a PEG ratio of 1.24 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same period last year, the company earned $1.14 EPS. Pfizer’s revenue for the quarter was down 41.3% compared to the same quarter last year. On average, equities analysts forecast that Pfizer Inc. will post 2.22 EPS for the current year.

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent analyst reports. Barclays reduced their price target on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a research report on Thursday, December 14th. Truist Financial decreased their target price on Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 14th. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Friday, March 1st. Guggenheim assumed coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Twelve investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.